SG10201909173PA - Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) - Google Patents

Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Info

Publication number
SG10201909173PA
SG10201909173PA SG10201909173PA SG10201909173PA SG 10201909173P A SG10201909173P A SG 10201909173PA SG 10201909173P A SG10201909173P A SG 10201909173PA SG 10201909173P A SG10201909173P A SG 10201909173PA
Authority
SG
Singapore
Prior art keywords
tim
chain polypeptide
directed against
immunoglobulin
cell immunoglobulin
Prior art date
Application number
Inventor
Marilyn Kehry
David J King
Silva Correia Jean Da
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of SG10201909173PA publication Critical patent/SG10201909173PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

OF THE DISCLOSURE ANTIBIOTICS DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3) The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease. (Figure 1A)
SG10201909173P 2015-04-01 2016-04-01 Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) SG10201909173PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562141353P 2015-04-01 2015-04-01

Publications (1)

Publication Number Publication Date
SG10201909173PA true SG10201909173PA (en) 2019-11-28

Family

ID=57007695

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909173P SG10201909173PA (en) 2015-04-01 2016-04-01 Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201707705UA SG11201707705UA (en) 2015-04-01 2016-04-01 Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707705UA SG11201707705UA (en) 2015-04-01 2016-04-01 Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

Country Status (15)

Country Link
US (3) US10508149B2 (en)
EP (1) EP3277321A4 (en)
JP (1) JP6949717B2 (en)
KR (1) KR20170133458A (en)
CN (2) CN107847589B (en)
AU (1) AU2016242964C1 (en)
BR (1) BR112017021040A2 (en)
CA (1) CA2981520A1 (en)
EA (1) EA201792184A1 (en)
HK (1) HK1251150A1 (en)
IL (2) IL283006B2 (en)
MA (1) MA41867A (en)
MX (1) MX2017012429A (en)
SG (2) SG10201909173PA (en)
WO (1) WO2016161270A1 (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
HUE048111T2 (en) 2015-03-23 2020-05-28 Bayer Pharma AG Anti-ceacam6 antibodies and uses thereof
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JOP20190013A1 (en) 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
MA46113A (en) 2016-11-01 2019-07-10 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST T-LYMPHOCYTE IMMUNOGLOBULIN AND MUCINE PROTEIN 3 (TIM-3)
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108101989A (en) * 2016-11-24 2018-06-01 复旦大学 For the full people source single domain antibody of people TIM-3 and application
JOP20190133A1 (en) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
CN110023338A (en) * 2016-12-08 2019-07-16 伊莱利利公司 For the anti-TIM-3 antibody with anti-PD-L1 antibody combination
TWI665216B (en) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 Anti-human tim-3 antibodies and methods of use thereof
CN110382000A (en) 2017-01-09 2019-10-25 泰萨罗公司 With the method for anti-TIM-3 antibodies for treating cancer
PL3565844T3 (en) 2017-01-09 2023-06-12 Tesaro Inc. Methods of treating cancer with anti-pd-1 antibodies
CN109983032B (en) 2017-02-27 2022-07-26 江苏恒瑞医药股份有限公司 TIM-3 antibodies, antigen-binding fragments thereof, and medical uses thereof
CN110799541A (en) 2017-04-27 2020-02-14 特沙诺有限公司 Antibody agents against lymphocyte activation gene-3 (LAG-3) and uses thereof
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
KR20200019865A (en) 2017-06-22 2020-02-25 노파르티스 아게 IL-1beta binding antibody for use in cancer treatment
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
JP2021500916A (en) 2017-07-28 2021-01-14 フェインズ セラピューティクス，インコーポレーテッド Anti-TIM-3 antibody and its use
EP3676616A1 (en) 2017-08-28 2020-07-08 Bristol-Myers Squibb Company Tim-3 antagonists for the treatment and diagnosis of cancers
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations
US11661453B2 (en) 2017-09-30 2023-05-30 Tesaro, Inc. Combination therapies for treating cancer with niraparib and PD-1 inhibitors
EP3691685A1 (en) 2017-10-06 2020-08-12 Tesaro Inc. Combination therapies and uses thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019196911A1 (en) 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Antibody binding tim-3 and use thereor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019204655A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
BR122022012697B1 (en) 2018-07-10 2023-04-04 Novartis Ag USES OF 3-(5-HYDROXY-1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6- DIONE DERIVATIVES, AND KIT
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
KR20210046701A (en) 2018-08-20 2021-04-28 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Use of TIM-3 antibodies in the manufacture of drugs for the treatment of tumors
AU2019330702A1 (en) 2018-08-28 2021-04-08 Jiangsu Hengrui Medicine Co., Ltd. Anti-TIM3 antibody pharmaceutical composition and use thereof
TW202024638A (en) * 2018-09-04 2020-07-01 美商泰沙羅公司 Methods of treating cancer
AU2019351255A1 (en) 2018-09-26 2021-04-29 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
JP7472115B2 (en) 2018-10-03 2024-04-22 テサロ， インコーポレイテッド Niraparib salt
JP2022504228A (en) 2018-10-03 2022-01-13 テサロ， インコーポレイテッド Crystal form of niraparib free base
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR20210104094A (en) * 2018-12-12 2021-08-24 우시 바이올로직스 아일랜드 리미티드 Anti-TIM-3 Antibodies and Uses Thereof
MX2021007369A (en) 2018-12-19 2021-07-15 Bayer Ag Pharmaceutical combination of anti ceacam6 and tim3 antibodies.
EP3898686A1 (en) 2018-12-20 2021-10-27 Novartis AG Pharmaceutical combinations
BR112021011874A2 (en) 2018-12-20 2021-09-08 Novartis Ag DOSAGE SCHEME AND PHARMACEUTICAL COMBINATION INCLUDING DERIVATIVES OF 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
KR20210109564A (en) 2018-12-21 2021-09-06 옹쎄오 Novel conjugated nucleic acid molecules and uses thereof
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP2022514087A (en) 2018-12-21 2022-02-09 ノバルティス アーゲー Use of IL-1β binding antibody
KR20210108978A (en) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 Bifunctional Anti-PD-1/IL-7 Molecules
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
BR112021011351A2 (en) 2018-12-21 2021-11-16 Novartis Ag Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
AU2020221247A1 (en) 2019-02-12 2021-08-05 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
MX2021009763A (en) 2019-02-15 2021-09-08 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof.
KR20210129672A (en) 2019-02-15 2021-10-28 노파르티스 아게 Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020192709A1 (en) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific polypeptide complexes
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
JP2022534981A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and combination treatments
WO2020257789A2 (en) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tim-3 antibodies
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
BR112022001881A2 (en) 2019-08-29 2022-06-21 Astellas Pharma Inc Genetically manipulated oncolytic vaccinia virus and methods of using it
CN114423786A (en) 2019-09-16 2022-04-29 诺华股份有限公司 Use of high affinity, ligand blocking, humanized anti-T cell immunoglobulin domain and mucin domain 3(TIM-3) IgG4 antibodies for the treatment of myelofibrosis
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
TW202128166A (en) 2019-10-21 2021-08-01 瑞士商諾華公司 Combination therapies
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
TW202136287A (en) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 Bifunctional molecules comprising an il-7 variant
CN115298218A (en) 2019-12-18 2022-11-04 特沙诺有限公司 Biopharmaceutical compositions and related methods
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022012310A2 (en) 2020-01-17 2022-09-06 Novartis Ag A COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETYLING AGENT FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
EP4136113A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
TW202214857A (en) 2020-06-19 2022-04-16 法商昂席歐公司 New conjugated nucleic acid molecules and their uses
BR112022026202A2 (en) 2020-06-23 2023-01-17 Novartis Ag DOSAGE REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONE DERIVATIVES
CN116134027A (en) 2020-08-03 2023-05-16 诺华股份有限公司 Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
WO2023031366A1 (en) 2021-09-02 2023-03-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3150340B2 (en) 1990-11-13 2001-03-26 イムネクス コーポレイション Bifunctional selectable fusion gene
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO2001057219A2 (en) 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
FR2814642B1 (en) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
ES2307832T3 (en) 2001-12-03 2008-12-01 Amgen Fremont Inc. ANTIBODY CLASSIFICATION BASED ON THE CHARACTERISTICS OF UNION.
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
JP2005523018A (en) * 2002-04-17 2005-08-04 メッツ リチャード Homologous replacement of short fragments to provide BSE resistant cattle
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
PL2046833T3 (en) 2006-07-14 2014-01-31 Ac Immune Sa Humanized antibody against amyloid beta
JP5577543B2 (en) 2006-09-08 2014-08-27 アムジエン・インコーポレーテツド IL-1 family variant
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008103475A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
SI2170959T1 (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN101932572A (en) 2008-01-08 2010-12-29 默沙东有限公司 2-{4-[(3S)-and piperidines-3-yl] phenyl }-pharmacologically acceptable salts of 2H-indazole-7-carboxylic acid amides
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
CA2721231C (en) 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
AU2011262758B8 (en) * 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
MX2014002289A (en) * 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Tandem fc bispecific antibodies.
EP3536710A1 (en) 2011-11-16 2019-09-11 Boehringer Ingelheim International GmbH Anti il-36r antibodies
CN102492038B (en) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
JP6242808B2 (en) 2011-12-28 2017-12-06 イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ Methods for providing monoclonal autoantibodies having a desired specificity
JP6433889B2 (en) * 2012-06-15 2018-12-05 ファイザー・インク Improved antagonistic antibodies against GDF-8 and uses thereof
WO2014165115A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
ES2926773T3 (en) 2013-03-15 2022-10-28 Novo Nordisk As Antibodies capable of specifically binding to two epitopes on the tissue factor pathway inhibitor
US9815897B2 (en) * 2013-05-02 2017-11-14 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
KR102442436B1 (en) 2014-03-14 2022-09-15 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
KR102011205B1 (en) 2014-11-06 2019-08-14 에프. 호프만-라 로슈 아게 Anti-tim3 antibodies and methods of use
GB201421430D0 (en) 2014-12-02 2015-01-14 Medimmune Llc Antibodies to Adam17 and uses thereof
MA41463A (en) 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
CN107849124B (en) 2015-06-05 2021-09-24 基因泰克公司 anti-TAU antibodies and methods of use
PT3317301T (en) 2015-07-29 2021-07-09 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108697791B (en) 2015-11-03 2022-08-23 詹森生物科技公司 Antibodies that specifically bind to PD-1 and uses thereof
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
MA46113A (en) 2016-11-01 2019-07-10 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST T-LYMPHOCYTE IMMUNOGLOBULIN AND MUCINE PROTEIN 3 (TIM-3)
CN110382000A (en) 2017-01-09 2019-10-25 泰萨罗公司 With the method for anti-TIM-3 antibodies for treating cancer
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES

Also Published As

Publication number Publication date
IL254559B2 (en) 2023-07-01
IL283006B1 (en) 2023-06-01
CA2981520A1 (en) 2016-10-06
JP6949717B2 (en) 2021-10-13
AU2016242964A1 (en) 2017-11-09
IL254559A (en) 2019-02-10
KR20170133458A (en) 2017-12-05
SG11201707705UA (en) 2017-10-30
JP2018512138A (en) 2018-05-17
US20200148770A1 (en) 2020-05-14
IL283006A (en) 2021-06-30
AU2016242964C1 (en) 2022-06-09
WO2016161270A1 (en) 2016-10-06
EP3277321A4 (en) 2018-12-12
MX2017012429A (en) 2018-01-26
CN107847589B (en) 2022-03-29
IL254559B1 (en) 2023-03-01
EA201792184A1 (en) 2018-04-30
CN114539409A (en) 2022-05-27
US20180127500A1 (en) 2018-05-10
BR112017021040A2 (en) 2018-07-24
IL283006B2 (en) 2023-10-01
AU2016242964B2 (en) 2022-01-13
CN107847589A (en) 2018-03-27
EP3277321A1 (en) 2018-02-07
US11352427B2 (en) 2022-06-07
HK1251150A1 (en) 2019-01-25
MA41867A (en) 2018-02-06
US20220363759A1 (en) 2022-11-17
US10508149B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
SG10201909173PA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MX2023001791A (en) Antibodies directed against interleukin 36 receptor (il-36r).
MX2019005116A (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3).
MX2022000112A (en) Antibodies directed against lymphocyte activation gene 3 (lag-3).
MX2020001272A (en) Antibodies directed against interleukin-33 (il-33).
MX2019000443A (en) Antibodies against tim3 and uses thereof.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
MX2019012793A (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof.
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2019003058A (en) The novel monoclonal antibodies to programmed death 1 (pd-1).
MX2015015037A (en) Antibodies directed against programmed death-1 (pd-1).
MD4716C1 (en) Anti-LAG3 antibodies and antigen-binding fragments
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2015187521A3 (en) Anti-blys antibodies
WO2014172448A3 (en) Antibodies directed against activin receptor type ii (actrii)
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
EA201990743A1 (en) ANTIBODIES AIMED AGAINST PROTEIN-3 CONTAINING T-CELL IMMUNOGLOBULIN AND MUCIN (TIM-3)
MX2016011177A (en) Antibodies to matrix metalloproteinase 9 and methods of use thereof.
EA201792460A1 (en) CONNECTING TIGIT AGENTS AND OPTIONS FOR THEIR APPLICATION